NCT03692429 - alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

November 28, 2021

Study Completion Date

February 17, 2036

Conditions

Unresectable Metastatic Colorectal Cancer

Interventions

DRUG

CYAD-101

Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells

DRUG

FOLFOX

5-FU, leucovorin and oxaliplatin

DRUG

FOLFIRI

5-FU, leucovorin and irinotecan

Trial Locations (4)

RECRUITING

Institut Jules Bordet, Brussels

RECRUITING

UZ Antwerpen, Edegem

RECRUITING

UZ Leuven, Leuven

NOT_YET_RECRUITING

Moffit Cancer Center, Tampa